Home › NDC Lookup › RxCUI directory › RxCUI 602393

Abacavir 600 MG / lamivudine 300 MG Oral Tablet — RxCUI 602393

RxNorm drug concept · Semantic clinical drug
RxCUI 602393 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI602393
Official nameAbacavir 600 MG / lamivudine 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asabacavir 600 MG / 3TC 300 MG Oral Tablet; abacavir sulfate 600 MG / lamiVUDine 300 MG Oral Tablet; abacavir (as abacavir sulfate) 600 MG / lamivudine 300 MG Oral Tablet
FDA products mapped6
Package NDCs mapped10
Reported Medicaid activity (SDUD)2,578 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lamivudine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It can be used for both, but here's the important thing: there are two different products, and they are not the same. The higher-dose tablets and oral solution (like Epivir) are us...
  • What exactly is lamivudine used for — is it for HIV or hepatitis B?
  • Please don't stop without talking to your doctor first. If you have HIV-1, stopping can allow the virus to rebound. If you're also infected with hepatitis B, stopping lamivudine ca...
  • Can I stop taking lamivudine if I feel fine?
📖 Read our full Lamivudine guide →

🕸️ Concept Web — How Abacavir 600 MG / lamivudine 300 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Abacavir 600 MG / lamivudine 300 MG Oral Tablet RxCUI 602393

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Abacavir 190521
    • Lamivudine 68244
    • Abacavir / lamivudine 614534
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Epzicom 497184
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Abacavir / lamivudine Oral Tablet 476143
    • Abacavir / lamivudine Oral Product 1163060
    • Abacavir / lamivudine Pill 1163061
    • Abacavir / lamivudine Oral Tablet [Epzicom] 539824
    • Epzicom Oral Product 1167643
    • Epzicom Pill 1168234
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Abacavir 600 MG 602392
    • Lamivudine 300 MG 350655
    • Abacavir 600 MG / lamivudine 300 MG Oral Tablet [Epzicom] 602395
    • Abacavir 600 MG / lamivudine 300 MG [Epzicom] 602394

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Abacavir 600 MG SCDC · 602392
  • Lamivudine 300 MG SCDC · 350655
  • Abacavir / lamivudine Oral Tablet SCDF · 476143
  • Abacavir / lamivudine Oral Product SCDG · 1163060
  • Abacavir / lamivudine Pill SCDG · 1163061

Brand-Name Concepts

  • Abacavir 600 MG / lamivudine 300 MG Oral Tablet [Epzicom] SBD · 602395
  • Abacavir 600 MG / lamivudine 300 MG [Epzicom] SBDC · 602394
  • Abacavir / lamivudine Oral Tablet [Epzicom] SBDF · 539824
  • Epzicom Oral Product SBDG · 1167643
  • Epzicom Pill SBDG · 1168234
  • Epzicom BN · 497184

📦 FDA Products & Package NDCs

6 products · 10 package NDCs
10 package NDCs map to RxCUI 602393 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
31722-0838-30 1 BOTTLE in 1 CARTON (31722-838-30) / 30 TABLET, FILM COATE... ABACAVIR and LAMIVUDINE Camber Pharmaceuticals, Inc. 2025-04-16
33342-0440-07 30 TABLET, FILM COATED in 1 BOTTLE (33342-440-07) Abacavir and Lamivudine Macleods Pharmaceuticals Limited 2024-12-20
33342-0440-14 5 BLISTER PACK in 1 CARTON (33342-440-14) / 6 TABLET, FILM... Abacavir and Lamivudine Macleods Pharmaceuticals Limited 2024-12-20
33342-0440-98 10 BLISTER PACK in 1 CARTON (33342-440-98) / 6 TABLET, FILM... Abacavir and Lamivudine Macleods Pharmaceuticals Limited 2024-12-20
42385-0962-18 180 TABLET, FILM COATED in 1 BOTTLE (42385-962-18) Abacavir and Lamivudine Laurus Labs Limited 2022-07-25
42385-0962-30 30 TABLET, FILM COATED in 1 BOTTLE (42385-962-30) Abacavir and Lamivudine Laurus Labs Limited 2022-07-25
42385-0962-90 90 TABLET, FILM COATED in 1 BOTTLE (42385-962-90) Abacavir and Lamivudine Laurus Labs Limited 2022-07-25
65862-0335-10 10 BLISTER PACK in 1 CARTON (65862-335-10) / 10 TABLET, FIL... Abacavir and Lamivudine Aurobindo Pharma Limited 2018-11-15
65862-0335-30 1 BOTTLE in 1 CARTON (65862-335-30) / 30 TABLET, FILM COATE... Abacavir and Lamivudine Aurobindo Pharma Limited 2018-11-15
69097-0362-02 30 TABLET, FILM COATED in 1 BOTTLE (69097-362-02) Abacavir and Lamivudine Cipla USA Inc. 2017-03-29
Observed labelers: Laurus Labs Limited (3) · Macleods Pharmaceuticals Limited (3) · Aurobindo Pharma Limited (2) · Camber Pharmaceuticals, Inc. (1) · Cipla USA Inc. (1) · +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.4542
Range $1.4542–$1.4542 · middle 50% $1.4542–$1.4542 · 4 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.